ymjЯкутский медицинский журналYakut Medical Journal1813-19052312-1017ЯНЦ КМПymj-1535Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHСтратификация больных гастроинтестинальными стромальными опухолями по группам риска: определение целесообразности проведения адъювантной терапии и ее продолжительностиRisk groups stratification of patients with gastrointestinal stromal tumors: defining the feasibility of adjuvant therapy and its durationКорниловаА. Г.KornilovaA. G.

врач онколог; аспирант кафедры онкологии и торакальной хирургии

КогонияЛ. М.KogoniyaL. M.д.м.н., проф. ГбУЗ МО МОНИКИМоськинВ. Г.Mos’kinV. G.врач радиолог; ст. лаборантМордановС. В.MordanovS. V.к.м.н., зав. лаб. ОксенюкО. С.OksenyukO. S.к.м.н., руковод. центральной научно-исследовательской лаборатории МУЗ ПГКб; ФУВ ГбУЗ МО МОНИКИ им. М.Ф. ВладимирскогоRussian FederationГбУЗ МО МОНИКИRussian FederationГбУЗ МО МОНИКИ; ГбУЗ МОRussian FederationРостовского гос. мед. университетаRussian FederationГбОУ ВПО РостГМУ Минздрава РоссииRussian Federation201416092025031216Copyright © Корнилова А.Г., Когония Л.М., Моськин В.Г., Морданов С.В., Оксенюк О.С., 20252025Корнилова А.Г., Когония Л.М., Моськин В.Г., Морданов С.В., Оксенюк О.С.Kornilova A.G., Kogoniya L.M., Mos’kin V.G., Mordanov S.V., Oksenyuk O.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ymj.elpub.ru/jour/article/view/1535

Опыт проведения адъювантной терапии больных гастроинтестинальными стромальными опухолями (ГИСО) продемонстрировал высокую эффективность, позволив увеличить безрецидивную выживаемость пациентов почти в 2 раза. В настоящее время пациенты группы низкого риска после проведения радикального хирургического лечения остаются под динамическим наблюдением, больным ГИСО группы умеренного риска рекомендовано проведение адъювантной терапии иматинибом в течение 1 года, высокого риска – в течение 3 лет. В статье представлен обзор наиболее значимых прогностических факторов, анализ которых позволит клиническому онкологу наиболее точно стратифицировать больных по группам риска и тем самым увеличить эффективность проводимой таргетной терапии.

Experience of adjuvant therapy of patients with gastrointestinal stromal tumors (GISTs) has demonstrated high efficacy allowing almost two-fold increase of patients’ recurrence-free survival. Currently, low risk patients after radical surgical treatment are closely followed up; moderate risk GIST patients are recommended adjuvant therapy with imatinib for 1 year whereas those of high risk – for 3 years. This article presents the review of significant predictors, analysis of which shall let a clinical oncologist stratify patients into risk groups most precisely thus improving the efficacy of target therapy.

гастроинтестинальные стромальные опухолиадъювантная терапиягруппы рискаиматинибgastrointestinal stromal tumorsadjuvant therapyrisk groupimatinibReferencesНикулин М.П. Гастроинтестинальные стромальные опухоли (ГИСО). Эпидемиология, диагностика, современные подходы к лечению / М.П. Никулин, И.С. Стилиди // Современная онкология. Экстра выпуск. – 2007. С. 3-50.Nikulin M.P. Gastrointestinal stromal tumors (GIST). Epidemiology, diagnosis, modern approaches to treatment / Nikulin I.P., Stilidi I.S. // Contemporary Oncology. Extra issue. 2007. P. 3-50.Снигур П.В. Стромальные опухоли двенадцатиперстной кишки / П.В. Снигур, О.А. Анурова // хирургия. – 2003. №11. С. 46-48.Snigur P.V. Stromal tumors of the duodenum / P.V. Snigur, O.A. Anurova / / Surgery. 2003. №11. p. 46-48.An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas / К. Antman [et al.] // J Clin Oncol. – 1993. № 11(7). Р. 1276-1285.An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas / К. Antman [et al.] // J Clin Oncol. – 1993. № 11(7). Р. 1276-1285.Benjamin R.S. For the Sarcoma Intergroup. Phase III dose-randomized study of imatinib mesylate (ST1571) for GIST: Intergroup S0033 early results / R.S. Benjamin, С. Rankin, С. Fletcher //. Proc Am Soc Clin Oncol. 2003. - №22. Р. 814.Benjamin R.S. For the Sarcoma Intergroup. Phase III dose-randomized study of imatinib mesylate (ST1571) for GIST: Intergroup S0033 early results / R.S. Benjamin, С. Rankin, С. Fletcher //. Proc Am Soc Clin Oncol. 2003. - №22. Р. 814.Blackstein M.E. Risk assessment for tumor recurrence after surgical resection of localized primary gastrointestinal stromal tumor: North American Intergroup phase III trial ACOSOG Z9001/ М. е. Blackstein // GI ASCO. – 2010.- №6.Blackstein M.E. Risk assessment for tumor recurrence after surgical resection of localized primary gastrointestinal stromal tumor: North American Intergroup phase III trial ACOSOG Z9001/ М. е. Blackstein // GI ASCO. – 2010.- №6.CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34 / M. Sarlomo-Rikala [et al.] // Mod Pathol. l998.- № 11(8).P. 728-734.CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34 / M. Sarlomo-Rikala [et al.] // Mod Pathol. l998.- № 11(8).P. 728-734.Corless C.L. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib / C.L. Corless, A. Schroeder, D.J. Griffith // Clin. Oncol. – 2005. № 23. Р. 5357–5364.Corless C.L. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib / C.L. Corless, A. Schroeder, D.J. Griffith // Clin. Oncol. – 2005. № 23. Р. 5357–5364.Daum O. Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecular genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors / O. Daum, P. Grossmann, T. Vanecek // Ann. Diagn. Pathol. – 2007. № 11. – Р. 27–33.Daum O. Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecular genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors / O. Daum, P. Grossmann, T. Vanecek // Ann. Diagn. Pathol. – 2007. № 11. – Р. 27–33.Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis /J.S.Gold [et al.] // Lancet Oncol. 2009. №10(11). P. 1045-52.Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis /J.S.Gold [et al.] // Lancet Oncol. 2009. №10(11). P. 1045-52.ESMO Clinical Recommendations for diagnosis, treatment and follow-up. – 2010.Р. 147153.ESMO Clinical Recommendations for diagnosis, treatment and follow-up. – 2010.Р. 147153.ESMO Update Clinical Practice Guidelines. Ann of Oncol. 2012.№23.Supplement 7.ESMO Update Clinical Practice Guidelines. Ann of Oncol. 2012.№23.Supplement 7.European Organisation for Research and Treatment of Cancer. EORTC 62024 study protocol. Phase III randomized study of adjuvant imatinib mesylate versus observation only in patients with completely resected localized gastrointestinal stromal tumor at intermediateor high-risk of relapse. 18-FDG-PET provides early evidence of biological response to STI-571 in patients with malignant gastrointestinal stromal tumors / A.D. Van den Abbelle [et al.] // Proc Am Soc Clin Oncol. – 2001.№ 20.P. 362.European Organisation for Research and Treatment of Cancer. EORTC 62024 study protocol. Phase III randomized study of adjuvant imatinib mesylate versus observation only in patients with completely resected localized gastrointestinal stromal tumor at intermediateor high-risk of relapse. 18-FDG-PET provides early evidence of biological response to STI-571 in patients with malignant gastrointestinal stromal tumors / A.D. Van den Abbelle [et al.] // Proc Am Soc Clin Oncol. – 2001.№ 20.P. 362.Gastrointestinal stromal tumors (GISTs) of the jejunum and ileum: a clinicopathologic, immunohistochemical and molecular genetic study of 906 cases prior to imatinib with longterm follow-up / M. Miettinen [et al.]// Am. J Surg. Pathol. 2006.№30.P. 477–489.Gastrointestinal stromal tumors (GISTs) of the jejunum and ileum: a clinicopathologic, immunohistochemical and molecular genetic study of 906 cases prior to imatinib with longterm follow-up / M. Miettinen [et al.]// Am. J Surg. Pathol. 2006.№30.P. 477–489.Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management / I. Pidhorecky [et al.] // Ann Surg Oncol. – 2000.-№ 7(9).P.705-712.Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management / I. Pidhorecky [et al.] // Ann Surg Oncol. – 2000.-№ 7(9).P.705-712.Gain-function mutations of c-kit in human gastrointestinal stromal tumors/ S. Hirota [et al.] //Science. – 1998.№279.P. 577-580.Gain-function mutations of c-kit in human gastrointestinal stromal tumors/ S. Hirota [et al.] //Science. – 1998.№279.P. 577-580.Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal / L.G. Kindblom [et al.] // Am J Pathol. – 1998.№152(5).P.1259-69.Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal / L.G. Kindblom [et al.] // Am J Pathol. – 1998.№152(5).P.1259-69.High incidence of microscopic gastrointestinal stromal tumors in the stomach / K. Kawanowa [et al.] // Human Pathol. 2006. - №37(12). P. 1527-1535.High incidence of microscopic gastrointestinal stromal tumors in the stomach / K. Kawanowa [et al.] // Human Pathol. 2006. - №37(12). P. 1527-1535.Guillou L. Prognostic factors in soft tissue sarcoma in the adult/ L. Guillou, J.M.Coindre // Ann Pathol. 1997. №17(6). P. 375-377.Guillou L. Prognostic factors in soft tissue sarcoma in the adult/ L. Guillou, J.M.Coindre // Ann Pathol. 1997. №17(6). P. 375-377.Hassan I. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis / I. Hassan, Y.N. You., R. Shyyan // Ann Surg Oncol. 2008. №15(1).P. 52-59.Hassan I. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis / I. Hassan, Y.N. You., R. Shyyan // Ann Surg Oncol. 2008. №15(1).P. 52-59.Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor/ H. Joensuu H// Hum Pathol. – 2008.№ 39(10).P.1411-1419.Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor/ H. Joensuu H// Hum Pathol. – 2008.№ 39(10).P.1411-1419.Lasota J. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours /J.Lasota, M.Miettinen// Histopathology. – 2008. -№ 4.P.4–16.Lasota J. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours /J.Lasota, M.Miettinen// Histopathology. – 2008. -№ 4.P.4–16.Martin J. Deletions affecting codons 557558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS)/ J.Martin, J. Poveda, A.J. Llombart-Bosch //Clin. Oncol. – 2005.№23.P. 6190– 6198.Martin J. Deletions affecting codons 557558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS)/ J.Martin, J. Poveda, A.J. Llombart-Bosch //Clin. Oncol. – 2005.№23.P. 6190– 6198.Mazur M.T. Gastric stromal tumors: Reappraisal of histogenesis/ M.T. Mazur, H.B.Clark // Am J Surg. Pathol. – 1983.-№7.P.507-519.Mazur M.T. Gastric stromal tumors: Reappraisal of histogenesis/ M.T. Mazur, H.B.Clark // Am J Surg. Pathol. – 1983.-№7.P.507-519.Miettinen M. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review / M.Miettinen, W.El-Rifai // Hum Pathol. – 2002.№33.P. 478–483.Miettinen M. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review / M.Miettinen, W.El-Rifai // Hum Pathol. – 2002.№33.P. 478–483.Miettinen M. Gastrointestinal stromal tumors in patients with neurofibromatosis: a clinicopathologic and molecular genetic study of 45 cases / M. Miettinen, J.F. Fetsch, L.H. Sobin // Am. J. Surg. Pathol. 2006.№30.P. 90–96.Miettinen M. Gastrointestinal stromal tumors in patients with neurofibromatosis: a clinicopathologic and molecular genetic study of 45 cases / M. Miettinen, J.F. Fetsch, L.H. Sobin // Am. J. Surg. Pathol. 2006.№30.P. 90–96.Miettinen M. Gastrointestinal stromal tumors definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis / M. Miettinen, J. Lasota // Virchows Arch.-2001.-№438(1).-P.1-12.Miettinen M. Gastrointestinal stromal tumors definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis / M. Miettinen, J. Lasota // Virchows Arch.-2001.-№438(1).-P.1-12.Miettinen M. Gastrointestinal stromal tumors: definition, occurrence, pathology, differential diagnosis and molecular genetics / M. Miettinen, J. Lasota // Pol. J. Pathol. – 2003.- №54.P.3–24.Miettinen M. Gastrointestinal stromal tumors: definition, occurrence, pathology, differential diagnosis and molecular genetics / M. Miettinen, J. Lasota // Pol. J. Pathol. – 2003.- №54.P.3–24.Miettinen M. Gastrointestinal stromal tumours: review on morphology, molecular pathology, prognosis, and differential diagnosis / M. Miettinen // Arch Pathol Lab Med. 2006.- №130.P.1466–1478.Miettinen M. Gastrointestinal stromal tumours: review on morphology, molecular pathology, prognosis, and differential diagnosis / M. Miettinen // Arch Pathol Lab Med. 2006.- №130.P.1466–1478.Miettinen M. Gastrointestinal stromal tumors of the stomach—a clinicopathologic, immunohistochemical and molecular genetic study of 1756 cases with long-term follow-up / M. Miettinen, L.H. Sobin, J. Lasota // Am. J. Surg. Pathol. 2005.№29.P. 52–68.Miettinen M. Gastrointestinal stromal tumors of the stomach—a clinicopathologic, immunohistochemical and molecular genetic study of 1756 cases with long-term follow-up / M. Miettinen, L.H. Sobin, J. Lasota // Am. J. Surg. Pathol. 2005.№29.P. 52–68.Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations /A. Agaimy [et al.] //Am J Surg Pathol. – 2007.№31(1).Р.113120.Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations /A. Agaimy [et al.] //Am J Surg Pathol. – 2007.№31(1).Р.113120.Mudan S. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection / S. Mudan, K. Conlon, J.Woodruff // Canсer. – 2000.№ 88.P. 66-74.Mudan S. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection / S. Mudan, K. Conlon, J.Woodruff // Canсer. – 2000.№ 88.P. 66-74.One vs three years of adjuvant imatinib for operable GIST: a randomized trial / H. Joensuu [et al.] // JAMA. – 2012.№307(12). P.126572.One vs three years of adjuvant imatinib for operable GIST: a randomized trial / H. Joensuu [et al.] // JAMA. – 2012.№307(12). P.126572.Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study / M. Zalupski [et al.] //J Nat Cancer Inst. – 1991.№ 83(13).P. 926-932.Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study / M. Zalupski [et al.] //J Nat Cancer Inst. – 1991.№ 83(13).P. 926-932.Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging / E.H. Ng [et al.] // Ann Surg. – 1992.№215(1). P. 68-77.Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging / E.H. Ng [et al.] // Ann Surg. – 1992.№215(1). P. 68-77.Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors / S. Singer [et al.] // J Clin Oncol. – 2002.№ 20(18).P. 38983905.Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors / S. Singer [et al.] // J Clin Oncol. – 2002.№ 20(18).P. 38983905.Role of Ki-67 as a prognostic factor in gastrointestinal stromal tumors / В. Belev [et al.] //World J Gastroenterol. – 2013. № 19(4). Р. 523-527.Role of Ki-67 as a prognostic factor in gastrointestinal stromal tumors / В. Belev [et al.] //World J Gastroenterol. – 2013. № 19(4). Р. 523-527.Rutkowski P. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate / P. Rutkowski, Z. Nowecki, P. Nyckowski // J Surg Oncol. – 2006.- №93.P. 304–311.Rutkowski P. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate / P. Rutkowski, Z. Nowecki, P. Nyckowski // J Surg Oncol. – 2006.- №93.P. 304–311.

The authors declare that there are no conflicts of interest present.